SCYNEXIS, Inc. (SCYX)
3.785
-0.02
(-0.66%)
USD |
NASDAQ |
Oct 23, 16:00
3.77
-0.02
(-0.40%)
After-Hours: 20:00
SCYNEXIS Enterprise Value : -14.56M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | -14.56M |
| October 22, 2026 | -14.31M |
| October 21, 2026 | -14.56M |
| October 20, 2026 | -14.41M |
| October 19, 2026 | -15.80M |
| October 16, 2026 | -15.70M |
| October 15, 2026 | -13.32M |
| October 14, 2026 | -12.82M |
| October 13, 2026 | -12.52M |
| October 12, 2026 | -12.12M |
| October 09, 2026 | -11.62M |
| October 08, 2026 | -10.23M |
| October 07, 2026 | -4.659M |
| October 06, 2026 | -4.062M |
| October 05, 2026 | -2.172M |
| October 02, 2026 | -1.276M |
| October 01, 2026 | 1.211M |
| September 30, 2026 | -3.067M |
| September 29, 2026 | -5.853M |
| September 28, 2026 | -6.251M |
| September 25, 2026 | -8.539M |
| September 24, 2026 | -7.942M |
| September 23, 2026 | -6.102M |
| September 22, 2026 | -3.863M |
| September 21, 2026 | -8.440M |
| Date | Value |
|---|---|
| September 18, 2026 | -7.843M |
| September 17, 2026 | -7.942M |
| September 16, 2026 | -11.33M |
| September 15, 2026 | -8.539M |
| September 14, 2026 | -6.450M |
| September 11, 2026 | -4.062M |
| September 10, 2026 | -5.455M |
| September 09, 2026 | -3.366M |
| September 08, 2026 | -0.9776M |
| September 04, 2026 | 0.5149M |
| September 03, 2026 | 0.9626M |
| September 02, 2026 | -0.2811M |
| September 01, 2026 | -0.7786M |
| August 31, 2026 | -0.1816M |
| August 28, 2026 | 1.410M |
| August 27, 2026 | 2.704M |
| August 26, 2026 | 4.196M |
| August 25, 2026 | -0.5796M |
| August 24, 2026 | 0.1169M |
| August 21, 2026 | -1.475M |
| August 20, 2026 | -0.2811M |
| August 19, 2026 | -0.9776M |
| August 18, 2026 | -1.077M |
| August 17, 2026 | -1.574M |
| August 14, 2026 | -0.6791M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.903B |
| Corcept Therapeutics, Inc. | 8.967B |
| Veru, Inc. | 15.08M |
| Johnson & Johnson | 662.44B |
| Eli Lilly & Co. | 1.245T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 7.397M |
| Revenue (Quarterly) | 0.235M |
| Total Expenses (Quarterly) | -7.162M |
| EPS Diluted (Quarterly) | 0.6256 |
| Earnings Yield | -48.70% |
| Normalized Earnings Yield | -58.18 |